Stephen Knight

Stephen Knight joined F-Prime Capital in 2003 where he serves as President and Managing Partner. He has worked in the pharmaceutical and biotechnology industries for over 25 years and invests broadly across healthcare. Dr. Knight also serves on the board of directors of Atalanta Therapeutics, Beam Therapeutics (NASDAQ: BEAM), Ensoma, Geneception, Genomics plc, Iora Health, Leyden Labs, Pulmocide and Sana Biotechnology. Prior to joining F-Prime Capital, he held various senior management roles in private and public biotechnology and consulting companies.